ePD Management Team
Donald E. Mager, Pharm.D., Ph.D.
President and CEO
Don is a founder and serves as President and Chief Executive Officer (CEO) of ePD. He is primarily responsible for new business development, client relations, and oversight of all scientific and business activities at ePD.
Don received a Pharm.D. and Ph.D. degree in Pharmaceutical Sciences from the State University of New York (SUNY) at Buffalo. Don has accumulated 15+ years of experience in partnering with pharmaceutical companies, the FDA, and research institutes on applications of pharmacometric and systems modeling in drug development and pharmacotherapy. Don has contributed to over 130 peer-reviewed publications and brings a unique and global perspective to developing pharmacometric and systems-based strategies in drug development and understanding sources of individual and population-level variability in drug responses.
Don is a Professor of Pharmaceutical Sciences at SUNY at Buffalo and has served as a Visiting Professor at the University Paris Descartes from 2007 to 2013. He currently serves on the Pharmaceutical Sciences and Clinical Pharmacology Advisory Committee to the FDA and as an expert member of the Board of Pharmaceutical Sciences at FIP. Don also serves as an Associate or Consulting Editor at CPT:Pharmacometrics & Systems Pharmacology (CPT:PSP), and Pharmacology, Research & Perspectives (PRP). Don is a Fellow and Past-President of the International Society of Pharmacometrics (ISoP) and is a Fellow and will be President-Elect of the American College of Clinical Pharmacology (ACCP). Don is also a Fellow of the American Association of Pharmaceutical Scientists (AAPS) and the American Association for the Advancement of Science (AAAS).
Scott A. Van Wart, M.S., Ph.D.
Vice President and CSO
Scott is a founder and serves as Vice President and Chief Scientific Officer (CSO) of ePD. He is primarily responsible for all operational aspects, as well as the execution and supervision of all scientific activities at ePD.
Scott received a Ph.D. degree in Pharmaceutical Sciences at the State University of New York (SUNY) at Buffalo. Scott has worked as a consultant for 19 years and has collaborated with many pharmaceutical companies to plan and implement modeling and simulation strategies to support drug development and commercialization programs. Scott has considerable experience helping Sponsors leverage the insight gained from PK and PK-PD analyses to guide decision making at critical development milestones in a variety of therapeutic areas, most notably for infectious and cardiovascular diseases. Scott’s broad range of pharmacometric expertise includes statistical analysis, population PK-PD analysis, physiologic- and mechanism-based systems modeling, optimal study design, and clinical trial simulation. Scott is the author or co-author of over 40 peer-reviewed scientific publications and book chapters.
In addition to his duties at ePD, Scott holds a position of Adjunct Professor and currently teaches biostatistics in the School of Pharmacy Practice at SUNY-Buffalo since 2013. Scott is a member of the International Society of Pharmacometrics and the American Society of Microbiology.